Introduction
============

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin\'s lymphoma (NHL), representing 30% of all lymphoma cases ([@b1-mco-0-0-02103]). The combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone is the first line immunochemotherapy used in the treatment of DLBCL, with cure rates of 60-70% ([@b2-mco-0-0-02103]). However, 30-40% of these patients will experience a relapse or refractory disease within the first 2-3 years following immunochemotherapy, thus exhibiting a poor prognosis ([@b5-mco-0-0-02103],[@b6-mco-0-0-02103]). Early relapses (≤1 year) and late relapses (\>5 years) may also occur, with incidence rates of 10-15 and 3%, respectively ([@b5-mco-0-0-02103],[@b7-mco-0-0-02103]).

High-dose immunotherapy followed by autologous stem cell transplantation (ASCT) is the standard treatment for patients with relapsed/refractory (RR) DLBCL that are \<65 years and without major comorbidities; however, \>60% of patients are ineligible for transplant, presenting a therapeutic challenge ([@b8-mco-0-0-02103]).

Promising immunotherapy approaches, including chimeric antigen receptor (CAR) T-cell therapy, have boosted the possibility of novel treatment options for patients with DLBCL ([@b2-mco-0-0-02103]). CAR T-cells are a form of immunotherapy in which immune cells are genetically engineered to target an antigen present on tumor cells so that they seek out those cells specifically; these T-cells then initiate an active and sustained immune response against the target cells ([@b9-mco-0-0-02103]).

Following years of research and development, the Food and Drug Administration (FDA) has already approved two CAR T-cell products. In October 2017, axicabtagene ciloleucel, marketed as Yescarta, became the first CAR T-cell therapy to be approved for patients with R/R NHL ([@b10-mco-0-0-02103]). Findings from phase II of the ZUMA-1 study revealed that the highest objective response rate (ORR) achieved using the therapy was 82%, and the highest complete remission (CR) rate was 54% ([@b11-mco-0-0-02103]). On a 12-month follow-up, the durable ORR was found to be 42%, and the durable CR rate was 40%. In May 2018, tisagenlecleucel was also approved for the treatment of large B-cell lymphoma, based on the phase II JULIET study; in the study, the highest reported ORR and CR rate were 52 and 40%, respectively ([@b12-mco-0-0-02103],[@b13-mco-0-0-02103]). Based on a European Hematology Association presentation, the durable ORR and CR rate are postulated to be 34 and 29%, respectively ([@b14-mco-0-0-02103]). A third CAR T-cell therapy, lisocabtagene maraleucel has also shown promise in a phase II study, which is also expected to lead to FDA approval ([@b15-mco-0-0-02103]). In the phase II TRANSCEND study, at the dose level being explored for FDA submission, the highest ORR and CR rate were 80 and 59%, respectively; at 6 months, the durable ORR was 47% and the durable CR rate was 41% ([@b15-mco-0-0-02103]).

CAR T cells have thus shown promising efficacy in patients with DLBCL, including those with R/R disease; however, this therapy is also associated with unexpected toxicities that can be life-threatening, including cytokine release syndrome (CRS) and neurotoxicity ([@b16-mco-0-0-02103]). Therefore, the challenges in DLBCL management are to reduce toxicity, prolong disease-free survival and determine factors that can predict relapse of DLBCL following CAR T-cell therapy.

The aim of the present study was to evaluate the general outcomes of CAR T-cell therapy in B-cell NHL, including the ORR and CR rate, progression-free survival (PFS), overall survival (OS) and adverse effects.

Materials and methods
=====================

### Meta-analysis

The meta-analysis was designed in accordance with the principles set by the PRISMA checklist ([@b17-mco-0-0-02103]). Inclusion criteria specified all clinical studies between 2010 and 2018 in which adult patients with DLBCL received the second generation of anti-CD19 or anti-CD20 CAR T-cell therapy. Ongoing clinical trials without reported outcomes and clinical trials with first-generation CAR T-cell therapy were excluded.

The literature search was performed using the following electronic medical bibliographic databases: PubMed (<https://pubmed.ncbi.nlm.nih.gov/>), Scopus ([www.scopus.com](www.scopus.com)), and Web of Science (<https://www.webofknowledge.com>). Relevant oncology conference proceedings were also searched. Terms used included 'anti-CD19', 'anti-CD20', 'diffuse large B-cell lymphoma', 'DLBCL', 'CAR T-cells' and 'chimeric antigen receptor T-cells'. The references of the retrieved articles and previous review articles were reviewed manually to obtain additional articles. Two investigators independently screened the retrieved titles and abstracts; the full texts were screened if the articles met the inclusion criteria. The full texts of these selected articles were obtained and evaluated by all investigators to confirm eligibility for inclusion ([Fig. 1](#f1-mco-0-0-02103){ref-type="fig"}).

Data were extracted using a structured template, and disagreements were resolved by consensus during the processes of screening and data extraction. For each study included, the following information was obtained: Author and year; phase of the study; patient population; CAR construct and signaling; dose of infused CAR T-cells; conditioning or lymphodepleting chemotherapy; origin type of the CAR T cells (autologous vs. donor-derived/allogeneic); outcomes; survival; and adverse effects. Second-generation CAR T-cell therapies in phase I and phase II clinical trials were selected for the final analysis. The primary outcome was ORR, while the secondary outcome was CR. Other secondary outcomes were PFS and OS. The toxicity data were analyzed in two main categories: Grade 3-4 CRS and severe neurotoxicity.

### Statistical analysis

The meta-analysis was performed using Comprehensive Meta-Analysis software (version 3.3.070; BioStat, Inc.) due to the small sample size in most of the studies included ([@b18-mco-0-0-02103]). The pooled odds ratios (event rate) estimates of ORR, CR and adverse events with 95% confidence intervals (CI) were obtained using the random-effects model. Statistical heterogeneity of the trials\' results was assessed via graphical inspections of the forest plots and by calculating a Chi-squared (χ^2^) test for heterogeneity with a significance level of P\<0.10.

Results
=======

### Clinical trial and patient clinical characteristics

The initial search identified 293 potentially relevant studies, and from those, a total of 11 clinical trials including 441 patients with B-cell lymphoma were included in the final analysis. Of these, 292 (66%) patients had *de novo* R/R DLBCL, 73 (17%) patients had transformed DLBCL from follicular lymphoma (FL), and 15 (3%) had transformed from chronic lymphocytic leukemia (CLL) or marginal zone lymphoma (MZL). Furthermore, 25 (6%) had FL, 18 (4%) had primary mediastinal large B-cell lymphoma (PMBCL), 14 (3%) had mantle cell lymphoma (MCL), and the remaining 4 patients had other B-cell lymphomas (1%). [Tables I-III](#tI-mco-0-0-02103 tII-mco-0-0-02103 tIII-mco-0-0-02103){ref-type="table"} present the characteristics and clinical outcomes of CAR T-cell therapy in the studies analyzed ([@b11-mco-0-0-02103],[@b13-mco-0-0-02103],[@b15-mco-0-0-02103],[@b19-mco-0-0-02103]).

### Efficacy

Over a median follow-up time of 19.6 months, response data were available for 419 of the patients with B-cell NHL. The pooled ORR (95% CI) was 69% (57-79%; [Fig. 2](#f2-mco-0-0-02103){ref-type="fig"}), and the pooled CR rate (95% CI) was 49% (44-52%; [Fig. 3](#f3-mco-0-0-02103){ref-type="fig"}).

A total of 306 patients with *de novo* or transformed DLBCL were eligible for response rate evaluation. The ORR was 68% (55-79%; [Fig. 4](#f4-mco-0-0-02103){ref-type="fig"}) and the CR rate was 46% (38-54%; [Fig. 5](#f5-mco-0-0-02103){ref-type="fig"}).

The PFS was reported for 234 patients with B-cell lymphoma from the 11 clinical trials, and at 12 months, the PFS was 43% (95% CI, 35-75%). The median and mean PFS durations were 4.5 and 4.1 months (95% CI, 1.5-5.9 months), respectively (data not shown).

The OS was reported for 317 patients, and at 12 months, it was 58% (95% CI, 49-60%). The median and mean OS durations were 13.2 and 14.2 months (95% CI, 8.3-22.2 months), respectively (data not shown).

### Safety

Safety was evaluated for 421 patients ([Table III](#tIII-mco-0-0-02103){ref-type="table"}). The most frequently reported grade ≥3 adverse effects were anemia in 34% of patients (95% CI, 25-45%), thrombocytopenia at 30% (95% CI, 18-46%), and febrile neutropenia at 19% (95% CI, 9-36%). The risks of grade ≥3 CRS and neurotoxicity in patients were 18% (95% CI, 11-27%) and 19% (95% CI, 12-28%), respectively ([Fig. 6](#f6-mco-0-0-02103){ref-type="fig"}).

### Heterogeneity

Statistical heterogeneity was observed among the 11 clinical trials in several outcomes, including ORR for patients with B-cell NHL (P=0.002; [Fig. 2](#f2-mco-0-0-02103){ref-type="fig"}), ORR for patients with DLBCL (P=0.007; [Fig. 4](#f4-mco-0-0-02103){ref-type="fig"}), and adverse events such as CRS (P=0.000), neurotoxicity (P=0.000), febrile neutropenia (P=0.001), anemia (P=0.003) and thrombocytopenia (P=0.016; [Fig. 6](#f6-mco-0-0-02103){ref-type="fig"}).

Discussion
==========

The efficacy of CAR T-cell immunotherapy has improved notably over the last decade. To date, three generations of CAR T-cells have been constructed; of these, the second and third generations of CAR T-cells show superior clinical outcomes relative to the first generation ([@b31-mco-0-0-02103]). It has been reported that first-generation CAR T-cells show decreased immune activation, limited efficacy and short duration of persistence, providing no evidence of clinical benefit for the treatment of B-cell NHL ([@b32-mco-0-0-02103]).

The present meta-analysis showed highly favorable clinical outcomes in patients with B-cell NHL that were treated with second-generation CAR T-cells. The results for 419 patients in 11 trials showed an ORR and CR rate mean estimate of 69% (95% CI, 57-79%) and 49% (95% CI, 44-52%), respectively. The response rates to CAR T-cells varied between different types of B-cell NHL. In 306 patients with R/R DLBCL eligible for rate evaluation, the ORR and CR rate mean estimates were 68% (95% CI, 55-79%) and 46% (95% CI, 38-54%), respectively; these results are comparable to the results reported on patients analyzed in the SCHOLAR-1 study, which showed an ORR of 26% and a CR rate of 7% with standard systemic therapy ([@b35-mco-0-0-02103]). Thus, the present findings suggested that CAR T-cell immunotherapy has significantly improved treatment outcomes for patients with R/R DLBCL, as well as other B-cell NHL subtypes. Comparisons between the reported outcomes in clinical trials included in the present study are difficult due to the clinical heterogeneity in the variables between clinical trials, including differences in patient populations, B-cell NHL subtypes disease specific variables, CAR T-cell methods, follow-up times and duration. Additionally, it has been suggested that the differences in clinical outcome could be due to clinical factors such as the CAR construct and signaling, conditioning or lymphodepleting chemotherapy, prior ASCT, prior treatments or other dissimilarities that will require further investigation ([@b36-mco-0-0-02103]). Given the consequences of clinical heterogeneity or methodological dissimilarities among CAR T-cell clinical trials included in this study, statistical heterogeneity was also observed for several outcomes, such as ORR and adverse events. Thus, a systematic review of literature is warranted following the present meta-analysis to summarize the evidence of relevant clinical factors that may have clinical utility in predicting CAR T-cell therapy clinical outcomes. Furthermore, with an increased number of clinical studies, detailed associations between clinical factors and clinical outcomes with CAR T-cell therapy will be uncovered further in the future.

The high response rates from second-generation CAR T-cells observed in the present analysis come with challenges posed by adverse events and toxicities of treatment. Evidence suggests that these adverse events tend to occur rapidly within the first few weeks of treatment and can cause potentially life-threatening complications ([@b28-mco-0-0-02103],[@b29-mco-0-0-02103]). In 419 patients with B-cell NHL evaluated for safety, it was observed that grade ≥3 anemia (34%; 95% CI, 25-45%) and thrombocytopenia (30%; 95% CI, 18-46%) were the most common adverse effects of CAR T-cell therapy. Additionally, grade ≥3 CRS and neurotoxicity were estimated in 18% (95% CI, 11-27%) and 19% (95% CI, 12-28%) of the patients, respectively. In the present analysis, incidence of CRS and neurotoxicity varied greatly in trials. The study by Kochenderfer *et al* ([@b29-mco-0-0-02103]) reported the highest rates of grade 3 or higher CRS and neurotoxicity, which was 40% (95% CI, 19-65%). Based on a previous report, administration of interleukin (IL)-2 is associated with significant neurotoxicity in patients treated with CAR T-cells ([@b40-mco-0-0-02103]). Although IL-2 was not administered to patients in their study, neurological toxicity still occurred in certain patients. A potential factor to consider is that all patients had received cyclophosphamide and fludarabine lymphodepletion. Of note, all patients recovered completely from their neurological toxicities ([@b29-mco-0-0-02103]). In the Fred Hutchinson Cancer Research Center CAR T-cell clinical trial, grade ≥3 CRS and neurotoxicity were observed in 13% (95% CI, 5-29%) and 28% (95% CI, 15-46%) of patients, respectively, and these were predominantly observed in patients who had received cyclophosphamide and fludarabine lymphodepletion and higher CAR T-cell dose ([@b24-mco-0-0-02103]). A reduction in the CAR T-cell dose in subsequent patients achieved ORR and CR rates of 82 and 64%, respectively. In TRANSCEND trial, however, dose level was not associated with CRS or neurotoxicity ([@b39-mco-0-0-02103]). Of note, the relatively high CRS and neurotoxicity rates observed in single center studies are due to relatively small sample size; additionally, two of the trials are allogeneic CAR T-cells in origin ([@b24-mco-0-0-02103],[@b27-mco-0-0-02103],[@b28-mco-0-0-02103]).

Following the expansion of CAR T-cell clinical trials, the therapeutic procedures and treatment outcomes markedly improved. In the analysis of three front-running multi-center CAR T-cell clinical studies, highly comparable rates of grade ≥3 CRS and neurotoxicity were observed. In the ZUMA-1 trial, grade ≥3 CRS and neurotoxicity were observed in 11 and 32% of patients, respectively; despite the high rate of grade ≥3 neurotoxicity, patients were effectively managed and with extended follow-up, there were no new unexpected serious adverse events and no new-onset neurological events associated with the CAR T-cells ([@b11-mco-0-0-02103],[@b19-mco-0-0-02103]). In the JULIET trial, grade ≥3 CRS and neurotoxicity were observed in 22 and 12% of patients, respectively; all cases of severe CRS were reversible, and no deaths were reported ([@b13-mco-0-0-02103],[@b20-mco-0-0-02103],[@b21-mco-0-0-02103]). In the analysis of the TRANSCEND trial, lower rates of toxicities were observed, with grade ≥3 CRS occurring in only 1% of patients, whereas neurotoxicity presented in 13%; additionally, no deaths from CRS or neurotoxicity were reported in this trial ([@b15-mco-0-0-02103],[@b22-mco-0-0-02103]). In conclusion, the present meta-analysis reported on a large number of patients with B-cell NHL treated with second-generation CAR T-cells. The study showed a high clinical response rate to CAR T-cell therapy among patients with B-cell NHL, particularly with DLBCL, compared with standard chemotherapy regimens. Incidence of CRS and neurotoxicity associated with CAR T-cell therapy were effectively managed.

Not applicable.

Funding
=======

No funding was received.

Availability of data and materials
==================================

All data generated or analyzed during this study are included in this article.

Authors\' contributions
=======================

MAM was involved in the conception and design of the study, conducted data collection, analysis and interpretation, and drafted and critically revised the manuscript, assuming general responsibility and guaranteeing the scientific integrity of the study. MAF was involved in drafting the study, conducting data collection, analysis and interpretation, and critically revising the manuscript. EI participated in statistical analysis and interpretation, critical revision, and helped to draft and finalize the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
==========================================

Not applicable.

Patient consent for publication
===============================

Not applicable.

Competing interests
===================

The authors declare that they have no competing interests.

![Flow diagram of the study selection process.](mco-13-04-02103-g00){#f1-mco-0-0-02103}

![Forest plot of the ORR of patients with any B-cell lymphoma. Squares represent the event rates (square size reflects the study-specific statistical weight); horizontal lines represent the 95% CI; and diamonds represent the pooled estimate based on a random-effects model. ORR, objective response rate; CI, confidence interval.](mco-13-04-02103-g01){#f2-mco-0-0-02103}

![Forest plot of the CR rate of patients with any B-cell lymphoma. Squares represent the event rates (square size reflects the study-specific statistical weight); horizontal lines represent the 95% CI; and diamonds represent the pooled estimate based on a random-effects model. CR, complete remission; CI, confidence interval.](mco-13-04-02103-g02){#f3-mco-0-0-02103}

![Forest plot of the ORR of patients with diffuse large B-cell lymphoma. Squares represent the event rates (square size reflects the study-specific statistical weight); horizontal lines represent the 95% CI; and diamonds represent the pooled estimate based on a random-effects model. ORR, objective response rate; CI, confidence interval.](mco-13-04-02103-g03){#f4-mco-0-0-02103}

![Forest plot of the CR rate of patients with large B-cell lymphoma. Squares represent the event rates (square size reflects the study-specific statistical weight); horizontal lines represent the 95% CI; and diamonds represent the pooled estimate based on a random-effects model. CR, complete remission; CI, confidence interval](mco-13-04-02103-g04){#f5-mco-0-0-02103}

![Forest plot of the rates of adverse events (grade ≥3) in patients with any B-cell lymphoma. Squares represent the event rates (square size reflects the study-specific statistical weight); horizontal lines represent the 95% CI; and diamonds represent the pooled estimate based on random-effects model. CRS, cytokine release syndrome; CI, confidence interval.](mco-13-04-02103-g05){#f6-mco-0-0-02103}

###### 

Characteristics of second generation CAR T-cell clinical trials.

  Author, year                      Seq. no.   Project name                 Clinical trial phases    Construct name   Anti-   Co-stimulatory domain                      Origin type of the CAR T cell   Mode of transduction   Dose                                                                                                                                    Lymphodepleting                                                                                                                (Refs.)
  --------------------------------- ---------- ---------------------------- ------------------------ ---------------- ------- ------------------------------------------ ------------------------------- ---------------------- --------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------
  Locke *et al*, 2017               1          ZUMA 1 Trial (a)             Phase 1                  KTE-C19          CD19    CD28                                       Autologous                      Retroviral vector      1-2x10^6^ CAR T cells/kg (patients \>100 kg: 2.0x10^8^ fixed dose)                                                                      Cy (500 mg/m^2^) and Flu (30 mg/m^2^) for 3 days                                                                               ([@b19-mco-0-0-02103])
  Neelapu *et al*, 2017             2          ZUMA 1 Trial (b)             Phase 2 (cohort no. 1)   KTE-C19          CD19    CD28                                       Autologous                      Retroviral vector      2.0x10^6^ CAR T cells/kg                                                                                                                Flu (30 mg/m^2^) and Cy (500 mg/m^2^) on days -5, -4 and -3                                                                    ([@b11-mco-0-0-02103])
  Schuster *et al*, 2017 and 2019   3          JULIET                       Phase 2                  CTL019           CD19    4-1BB                                      Autologous                      Lentiviral vector      Median, 3.1x10^8^ transduced cells (range, 0.1-6.0x10^8^ transduced cells)                                                              73% received Flu (25 mg/m^2^) + Cy (250 mg/m^2^/day) for 3 days; 20% received bendamustine (90 mg/m^2^/day) for 2 days         ([@b13-mco-0-0-02103],[@b20-mco-0-0-02103],[@b21-mco-0-0-02103])
  Abramson *et al*, 2017 and 2018   4          TRANSCEND                    Phase 1                  JCAR017          CD19    4-1BB Comprised of CD8 and CD4 1:1 ratio   Autologous                      Lentiviral vector      DL1 (singleinfusion): 5.0x10^7^ CAR T cells DL1 (double infusion): 5.0x10^7^ CAR T cells DL2 (single infusion): 1.0x10^8^ CAR T cells   Flu (30 mg/m^2^) and Cy (300 mg/m^2^) for 3 days                                                                               ([@b15-mco-0-0-02103],[@b22-mco-0-0-02103])
  Schuster *et al*, 2017            5          University of Pennsylvania   Phase 2                  CTL019           CD19    4-1BB CD3ζ and CD28                        Autologous                      Lentiviral vector      5.79x10^6^ (range, 3.08x10^6^-8.87x10^6^)                                                                                               Bendamustine, Cy                                                                                                               ([@b23-mco-0-0-02103])
  Turtle *et al*, 2016              6          Fred Hutch                   Phase 1                  huJCAR014        CD19    4-1BB Comprised of CD8 and CD4 1:1 ratio   Autologous                      Lentiviral vector      2x10^5^-2x10^7^ cells/kg                                                                                                                Cy (60 mg/kg) once + etoposide or Cy (60 mg/kg) once + Flu (25 mg/m^2^) for 3 days                                             ([@b24-mco-0-0-02103])
  Wang *et al*, 2014                7          NA                           Phase 1                                   CD 20   4-1BB CD137-CD3ζ                           Autologous                      Lentiviral vector      Not Recorded                                                                                                                            Cy, vincristine, doxorubicin, etoposide and carboplatin cytarabine                                                             ([@b25-mco-0-0-02103])
  Wang *et al*, 2016                8          NHL2                         Phase 1                                   CD 19   CD28                                       Autologous                      Lentiviral vector      5x10^7^-2x10^8^                                                                                                                         Autologous stem-cell transplantation                                                                                           ([@b26-mco-0-0-02103])
  Brudno *et al*, 2016              9          NA                           Phase 1                  Allogeneic       CD19    CD28-CD3ζ                                  Allogenic CD3ζ-28               Retroviral vector      0.7x10^6^-8.2x10^6^                                                                                                                     None                                                                                                                           ([@b27-mco-0-0-02103])
  Brudno *et al*, 2016              10         NA                           Phase 1                  HuCAR-19         CD19    CD28-CD3ζ                                  Allogenic                       Lentiviral vector      0.4-8.2x10^6^ cells/kg                                                                                                                  Cy (300 mg/m^2^) daily for 3 days + Flu (30 mg/m^2^) daily for 3 days                                                          ([@b28-mco-0-0-02103])
  Kochenderfer *et al*, 2015        11         NA                           Phase 1                                   CD19    CD28-CD3ζ                                  Autologous                      Retroviral vector      1-2.5x10^6^ cells/kg                                                                                                                    Bendamustine; Bendamustine/Rituximab; Pentostatin/Cy                                                                           ([@b29-mco-0-0-02103])
  Kochenderfer *et al*, 2017        12         NA                           Phase 1                                   CD19    CD 28                                      Autologous                      Retroviral vector      1-2x10^6^ CAR T cells/kg                                                                                                                Cy (300 mg/m^2^ or 500 mg/m^2^) intravenously daily for 3 days, and Flu (30 mg/m^2^) daily for 3 days ([@b30-mco-0-0-02103])   ([@b30-mco-0-0-02103])

CAR, chimeric antigen receptor; DL, dose level; Cy, cyclophosphamide; Flu, fludarabine.

###### 

Chimeric antigen receptor T-cell clinical trial outcomes.

  Author, year                      Seq. no.   Project name                 Median age     N                                               Histological subtypes                                                                                                          Median follow-up   B-cell NHL treatment outcome                                                            DLBCL treatment outcome                                                                                                                                                                                                  Duration of response                                                                           PFS/OS                                                                                                                                                         (Refs.)
  --------------------------------- ---------- ---------------------------- -------------- ----------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------ ------------------ --------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------
  Locke *et al*, 2017               1          ZUMA 1 Trial (a)             59             7                                               DLBCL (n=7)                                                                                                                    9 months           ORR, 71% (n=5/7);                                                                       ORR, 71% (n=5/7);                                                                                                                                                                                                        Not reported CR, 57% (n=4/7) CR, 57% (n=4/7); ongoing CR, 42% at 1 year of follow-up (n=3/7)   Not reported                                                                                                                                                   ([@b19-mco-0-0-02103])
  Neelapu *et al*, 2017             2          ZUMA 1 Trial (b)             58             101                                             DLBCL (n=77), PMBCL (n=8), transformed FL (n=16)                                                                               27 months          ORR, 83% (n=84/101); CR, 58% (n=59/101)                                                 ORR, 82% (n=63/77); CR, 49% (n=38/77); PR, 32% (n=25/77)                                                                                                                                                                 11.1 months for CR is not reached                                                              Median PFS, 5.9 months; PFS, 60% at 12 months; PFS, 35% at 24 months Median OS 12.8 months is not reached; OS, 60% at 12 months; OS, 50.5% at 24 months        ([@b11-mco-0-0-02103])
  Schuster *et al*, 2017 and 2019   3          JULIET                       56             111                                             R/R DLBCL (n=88), transformed FL (n=21), others (n=2)                                                                          28.6 months        ORR, 52% (n=48/93); CR, 40% (n=37/93)                                                   ORR, 52% (n=48/93); CR, 40% (n=37/93)                                                                                                                                                                                    Not reached                                                                                    Median PFS not reached; PFS, 65% at 12 months Median OS, 8.3 months; OS, 40% at 12 months                                                                      ([@b13-mco-0-0-02103],[@b20-mco-0-0-02103],[@b21-mco-0-0-02103])
  Abramson *et al*, 2017 and 2018   4          TRANSCEND                    61             102                                             *De novo* DLBCL (n=63), transformed from FL (n=23), transformed from other (MZL, CLL) (n=12), FL grade 3B (n=1), PMBCL (n=3)   8 months           ORR, 75% (n=73/102); CR, 52% (n=53/102)                                                 ORR, 80% (n=58/73); CR, 55% (n=40/73)                                                                                                                                                                                    9.2 months                                                                                     PFS not reported Median OS, 10.4 months; OS, 59% at 12 months                                                                                                  ([@b15-mco-0-0-02103],[@b22-mco-0-0-02103])
  Schuster *et al*, 2017            5          University of Pennsylvania   59             28                                              DLBCL (n=14), FL (n=14)                                                                                                        28.6 months        ORR, 64% (n=18/28); CR, 57% (n=16/28)                                                   ORR, 50% (n=7/14); CR, 43% (n=6/14) PFS was 3.2 months not reached, and 43% PFS at median follow-up (95% CI, 18-66%)                                                                                                     Not reached                                                                                    Median PFS, 3.2 months for DLBCL; PFS, 43% at 24 months Median OS, 22 months; OS, 47% at 24 months                                                             ([@b23-mco-0-0-02103])
  Turtle *et al*, 2016              6          Fred Hutch                   58             32                                              *De novo* aggressive B-cell lymphoma (n=11), transformed large B-cell lymphoma (n=11), FL (n=6), MCL (n=4)                                        ORR, 63% (n=19/30); CR, 33% (n=10/30)                                                   *De novo* aggressive B-cell lymphoma: ORR, 64% (n=7/11) De novo aggressive B-cell lymphoma: CR, 18% (n=2/11) Transformed large B-cell lymphoma: ORR, 70% (n=7/10) Transformed large B-cell lymphoma: CR, 60% (n= 6/10)                                                                                                  Median PFS follow-up for Cy and Cy/Flu, 1.5 and 5.8 months, respectively Median OS follow-up times for Cy and Cy/Flu, 25 months and 6.3 months, respectively   ([@b24-mco-0-0-02103])
  Wang *et al*, 2014                7          NA                           62             7                                               R/R DLBCL (n=7)                                                                                                                Not reported       ORR, 71% (n=5/7); CRR, 28% (n=2/7); PR, 43% (n=3/7); SD, 14% (n=1/7); PD, 14% (n=1/7)   ORR, 71% (5/7); CRR, 28% (2/7); PR, 43% (n=3/7); SD, 14% (n=1/7); PD, 14% (n=1/7)                                                                                                                                        Not reported                                                                                   Not reported                                                                                                                                                   ([@b25-mco-0-0-02103])
  Wang *et al*, 2016                8          NHL2                                        8                                               DBLCL (n=4), MCL (n=4)                                                                                                         12.3 months        Best ORR, 100% (n=8/8); best CR, 100% (n=8/8)                                           Best ORR, 100% (n=4/4); best CR, 100% (n=4/4)                                                                                                                                                                            Not reported                                                                                   PFS, 75% at 12 months                                                                                                                                          ([@b26-mco-0-0-02103])
  Brudno *et al*, 2016              9          NA                           Not reported   9                                               DLBCL (n=3), transformed FL (n=1), FL (n=2), MCL (n=1), B-cell lymphoma unclassified (n=1), Burkitt lymphoma (n=1)             Not reported       ORR, 86% (n=8/9); CR, 22% (n=2/9)                                                       ORR, 67% (n=2/3); CR, 33% (n=1/3)                                                                                                                                                                                        Not reported                                                                                   Not reported                                                                                                                                                   ([@b27-mco-0-0-02103])
  Brudno *et al*, 2016              10         NA                           48             10 (Total of 20, 10 excluded for ALL and CLL)   DLBCL (n=4), MCL (n=5), transformed FL to DLBCL (n=1), ALL (n=5), CLL (n=5)                                                    Not reported       ORR for NHL, 20% (n=2/10); CR, 10% (n=1/10)                                             ORR, 25% (n=1/4); CR, 25% (n=1/4)                                                                                                                                                                                        Not reported                                                                                   Not reported for NHL For all 20 patients: EFS, 39% at 6 months; 39%, at 12 months OS, 77% at 12 months                                                         ([@b28-mco-0-0-02103])
  Kochenderfer *et al*, 2015        11         NA                           47             11 (total of 15, 4 excluded for CLL)            DLBCL NOS (n=4), PMBCL (n=4), transformed DLBCL from CLL (n=1), indolent lymphomas (n=2)                                       Not reported       For NHL excluding CLL: ORR, 89% (n=8/9); for evaluable NHL: CR, 56% (n=5/9)             ORR, 100% (n= 3/3) for evaluable DLBCL; CR, 67% (n=2/3) for evaluable DLBCL                                                                                                                                              11 Months for NHL                                                                              Not reported                                                                                                                                                   ([@b29-mco-0-0-02103])
  Kochenderfer *et al*, 2017        12         NA                           47             7                                               DLBCL NOS (n=3), PMBCL (n=3), DLBCL from CLL (n=1)                                                                                                ORR, 86% (n=6/7); CR, 71% (n=5/7)                                                       ORR, 100 % (n=3/3); CR, 100% (n=3/3)                                                                                                                                                                                     Previously reported                                                                                                                                                                                                                                           ([@b30-mco-0-0-02103])

ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; NHL, non-Hodgkin\'s lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; NOS, not otherwise specified; PMBCL, primary mediastinal large B-cell lymphoma; R/R, relapsed/refractory; CI, confidence interval; CR, complete remission; ORR, objective response rate; PD, progressing disease; PR, partial response; SD, stable disease; EFS, event-free survival; PFS, progression-free survival; OS, overall survival.

###### 

Chimeric antigen receptor T-cell clinical trial toxicity profile.

  Author, year                      Seq. no.   Project name                 Toxicity: CRS and neurotoxicity                                                                                            Other toxicities, grade 3 or higher                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            (Refs.)
  --------------------------------- ---------- ---------------------------- -------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------
  Locke *et al*, 2017               1          ZUMA 1 Trial (a)             Grade 3-4 CRS, 11% (n=12/108) Neurotoxicity, 32% (n=35/108)                                                                Febrile neutropenia: Grade 3, 31% (n=33/108); grade 4, 2% (n=2/108) Neutropenia: Grade 3, 9% (n=10/108); grade 4, 30% (n=32/108) Anemia: Grade 3, 43% (n=46/108); grade 4, 3% (n=3/108) Thrombocytopenia: Grade 3, 10% (n=11/108); grade 4, 14% (n=15/108) Intracranial hemorrhage: Grade 3, 30%; grade 4, 0%; grade 5, 14% (n=1/7) Hypocalcemia: Grade 3, 6% (n=7/108); grade 4, 0% Hyponatremia: Grade 3, 11% (n=12/108); Grade 4, 0% Hypophosphatemia: Grade 3, 17% (n=18/108); Grade 4, 1% (n=1/108) Hypotension: Grade 3, 13% (n=14/108); Grade 4, 0% Fatigue: Grade 3, 3% (n=3/108); Grade 4, 0% Treatment-related death, 2% (n=2/108)   ([@b19-mco-0-0-02103])
  Neelapu *et al*, 2017             2          ZUMA 1 Trial (b)             Grade 3-4 CRS, 22% Neurotoxicity, 12%                                                                                      Febrile neutropenia, 15% Infection, 20% Cytopenia, 22% Tumor lysis syndrome, 1%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                ([@b11-mco-0-0-02103])
  Schuster *et al*, 2017 and 2019   3          JULIET                       Grade 3-4, 1% Grade 3-4 neurotoxicity, 12%                                                                                 Not reported                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   ([@b13-mco-0-0-02103],[@b20-mco-0-0-02103],[@b21-mco-0-0-02103])
  Abramson *et al*, 2017 and 2018   4          TRANSCEND                    Grade 3-4, 18% (n=5/28) Grade 3-4 neurotoxicity, 11% (n=3/28)                                                              Febrile neutropenia, 11% (n=3/28) Anemia, 11% (n=3/28) Atrial fibrillation, 4% (1/28) Intra-abdominal hemorrhage, 4% (n=1/28) Hypotension, 11% (n=3/28) Hypocalcemia, 4% (n=1/28) Hypercalcemia, 4% (n=1/28) Hyponatremia, 0% Hypomagnesemia, 0%                                                                                                                                                                                                                                                                                                                                                                                               ([@b15-mco-0-0-02103],[@b22-mco-0-0-02103])
  Schuster *et al*, 2017            5          University of Pennsylvania   Severe CRS, 13% (n=4/32) Grade 3-4 neurotoxicity, 28% (n=9/32)                                                             Not reported                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   ([@b23-mco-0-0-02103])
  Turtle *et al*, 2016              6          Fred Hutch                   Grade 3 CRS, 14% (n=1/7), Grade 4 CRS, 0% Grade 3-4 neurotoxicity, 0% Grade 3-4 alimentary tract hemorrhage, 29% (n=2/7)   Grade 4 infusion associated acute toxicities, 14% (n=1/7) Tumor lysis syndrome, 14% (n=1/7) Lung dysfunction, 14% (n=1/7) Serous cavity effusion, 14% (n=1/7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ([@b24-mco-0-0-02103])
  Wang *et al*, 2014                7          NA                           Grade 3-4 CRS, 0% (n=0/8) Neurotoxicity, 0% (n=0/8)                                                                        Hematological toxicities G4, 100% (n=8/8) Non hematological toxicity G3, 88% (n=7/8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ([@b25-mco-0-0-02103])
  Wang *et al*, 2016                8          NHL2                         Grade 3-4 CRS, 38% (n=3/8) Neurotoxicity, 13% (n=1/8)                                                                      Not reported                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   ([@b26-mco-0-0-02103])
  Brudno *et al*, 2016              9          NA                           Grade 3-4 CRS, 25% (n=1/4)                                                                                                 For NHL patients excluding leukemia patients: Grade 3-4 anemia, 10% (n=1/10) Grade 3-4 neutropenia, 20% (n=2/10) Grade 3-4 thrombocytopenia, 10% (n=1/10) Grade 3-4 AST/ALT elevation, 10% (n=1/10)                                                                                                                                                                                                                                                                                                                                                                                                                                            ([@b27-mco-0-0-02103])
  Brudno *et al*, 2016              10         NA                           Grade 3-4 CRS, 40% (n=6/15) Grade 3-4 neurotoxicity, 40% (n=6/15)                                                          Hypotension, 27% (n=4/15) Infection, 53% (n=8/15) Acute renal failure, 7%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      ([@b28-mco-0-0-02103])
  Kochenderfer *et al*, 2015        11         NA                           CRS Neurotoxicity                                                                                                          Previously reported                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            ([@b29-mco-0-0-02103])
  Kochenderfer *et al*, 2017        12         NA                           Grade 3-4 CRS, 11% (n=12/108) Neurotoxicity, 32% (n=35/108)                                                                Febrile neutropenia: Grade 3, 31% (n=33/108); grade 4, 2% (n=2/108) Neutropenia: Grade 3, 9% (n=10/108); grade 4, 30% (n=32/108) Anemia: Grade 3, 43% (n=46/108); grade 4 3% (n=3/108) Thrombocytopenia: Grade 3, 10% (n=11/108); grade 4, 14% (n=15/108) Intracranial hemorrhage: Grade 3, 30%; grade 4, 0%; grade 5, 14% (n=1/7) Hypocalcemia: Grade 3, 6% (n=7/108); grade 4, 0% Hyponatremia: Grade 3, 11% (n=12/108); grade 4, 0% Hypophosphatemia: Grade 3, 17% (n=18/108); grade 4, 1% (n=1/108) Hypotension: Grade 3, 13% (n=14/108); grade 4 0% Fatigue: Grade 3, 3% (n=3/108); grade 4, 0% Treatment-related death, 2% (n=2/108)     ([@b30-mco-0-0-02103])

CRS, cytokine release system; ALT, alanine transaminase; AST, aspartate transaminase; NHL, non-Hodgkin\'s lymphoma.
